{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-309137","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2022-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.571126+00:00","generated_at":"2026-06-21T01:47:57.735086+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaxcyte in option deal with Sutro for cell-free extract; $22.5M upfront","bullets":["Upfront consideration of $22.5M: $10M cash, $7.5M stock (due within 5-7 days), $5M after Form Definitive Agreement.","Option exercise price of $75M cash in two installments plus up to $60M in regulatory milestone payments.","Vaxcyte gains right to directly source cell-free extract from CMOs and option for exclusive internal manufacture/improvements.","Option period is five years, subject to acceleration upon change of control of Vaxcyte.","Agreement supports Vaxcyte's vaccine pipeline by securing supply and development rights for extract."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-309137","json":"https://secwatch.observer/filing/0001193125-22-309137.json","markdown":"https://secwatch.observer/filing/0001193125-22-309137.md","text":"https://secwatch.observer/filing/0001193125-22-309137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000119312522309137/0001193125-22-309137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000119312522309137/d432914d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T01:47:57.735086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"83868966eada196bedd79167d9135f9b0a425ec6","claim":"Vaxcyte, Inc. entered into Option Agreement with Sutro Biopharma, Inc. valued at $22.5 million (effective 2022-12-19).","evidence_excerpt":"On December 19, 2022 (the “Effective Date”), Vaxcyte, Inc. (“Vaxcyte”) entered into an option grant agreement (the “Option Agreement”) with Sutro Biopharma, Inc. (“Sutro,” and together with Vaxcyte, the “Companies”),","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649094/000119312522309137/0001193125-22-309137-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Sutro Biopharma, Inc."},{"label":"Value","value":"$22.5 million"},{"label":"Effective","value":"2022-12-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}